Lerkanidipina – antagonista wapnia o wyjątkowych właściwościach – dlaczego warto ją stosować w codziennej praktyce? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2014
Słowa kluczowe:
lerkanidipina, lipofilność, nefroprotekcja, obrzęki kończyn dolnych
##plugins.themes.bootstrap3.article.main##
Abstrakt
Lerkanidipina jest naczynioselektywnym, dihydropirydynowym antagonistą wapnia, o udowodnionym skutecznym działaniu hipotensyjnym. To najmłodszy przedstawiciel rodziny antagonistów wapnia, który dzięki właściwościom lipofilowym ma wolniejszy początek i dłuższy czas działania niż wielu innych antagonistów wapnia. Wyniki innych badań sugerują, że lerkanidipina może również chronić przed uszkodzeniami narządowymi i redukować postęp przewlekłej choroby nerek, co jest szczególnie ważne w grupie pacjentów z nadciśnieniem tętniczym. Równocześnie lerkanidipina jest lepiej tolerowana przez pacjentów niż większość innych antagonistów wapnia.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szymański , F. M. (2014). Lerkanidipina – antagonista wapnia o wyjątkowych właściwościach – dlaczego warto ją stosować w codziennej praktyce? . Medycyna Faktów , 7(4(25), 102-108. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2346
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bledowski P., Mossakowska M., Chudek J. et al.: Medical, psychological and socioeconomic aspects of aging in Poland: assumptions and objectives of the PolSenior project. Exp. Gerontol. 2011; 46: 1003-1009.
2. Głuszek J., Pawlaczyk K.: Działania niepożądane antagonistów wapnia. Choroby Serca i Naczyń 2006; 3: 18-31.
3. Charakterystyka produktu leczniczego Primacor [online: http://www.urpl.gov.pl/drugs/7758010].
4. Barrios V., Navarro A., Esteras A. et al.; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad): Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11: 95-100.
5. Barbagallo Sangiorgi G., Putignano E., Calcara L. et al.: Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S36-39.
6. James I.G.V., Jones A., Davies P.: A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J. Hum. Hypertens. 2002; 16: 605-610.
7. Morisco C., Trimarco B.: Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a doubleblind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S26-30.
8. Notarbartolo A., Rengo F., Scafidi V. et al.: Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr. Ther. Res. 1999; 60: 228-236.
9. Epstein M.: Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis. 2001; 3: 398-407.
10. Lund-Johansen P., Stranden E., Helberg S. et al.: Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 2003; 21: 1003-1010.
11. Ioulios P., Charalampos M., Efrossini T.: The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms. Dermatol. Online J. 2003; 9: 6.
12. Leonetti G.: The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 1999; 8: 92-101.
13. Fogari R., Malamani G.D., Zoppi A. et al.: Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel group study. Curr. Ther. Res. Clin. Exp. 2000; 61: 850-862.
14. Bang L.M., Chapman T.M., Goa K.L.: Lercanidipine. A Review of its Efficacy in the Management of Hypertension. Drugs 2003; 63: 2449-2472.
15. McClellan K.J., Jarvis B.: Lercanidipine: a review of its use in hypertension. Drugs 2000; 60: 1123-40.
16. Papavassiliou M.V., Vyssoulis G.P., Karpanou E.A. et al.: Side effects of antihypertensive treatment with calcium channel antagonists. Am. J. Hypertens. 2001; 14: 114A.
17. Barrios V., Escobar C., de la Figuera M. et al.: Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc. Ther. 2008; 26: 2-9.
18. Sabbatini M., Leonardi A., Testa R. et al.: Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-779.
19. Robles N.R., Romero B., de Vinuesa E.G. et al.: Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren. Fail. 2010; 32: 192-197.
20. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27: 73-80.
21. Leonardi A., Poggesi E., Taddei L. et al.: In vitro calcium antagonist activity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S10-18.
22. Meredith P.A.: Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Invest. Drug. 1999; 8: 1043-1062.
23. Guarneri L., Angelico P., Ibba M. et al.: Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittel Forschung 1996; 46: 15-24.
24. Angelico P., Guarneri L., Leonardi A. et al.: Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J. Pharm. Pharmacol. 1999; 51: 709-714.
25. Sironi G., Colombo D., Greto L. et al.: Antihypertensive activity of lercanidipine and its enantiomers in animal models. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S33-40.
26. Testa R., Rimoldi O., Sironi G. et al.: Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine and its enantiomers in conscious dogs. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): 78-85.
27. Guarneri L., Sironi G., Angelico P. et al.: In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S25-32.
28. Bianchi G., Passoni A., Griffini P.L.: Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol. Res. 1989; 21: 193-200.
29. Soma M.R., Natali M., Donetti E. et al.: Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br. J. Pharmacol. 1998; 125: 1471-1476.
30. Corsini A., Bonfatti M., Quarato P. et al.: Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol. 1996; 28: 687-694.
31. Harada N., Yamaguchi H., Shigematsu K. et al.: Effects of lercanidipine, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats [abstract]. SHR Congress. 1999 Aug 26-27; Sapporo.
32. Fogari R., Mugellini A., Corradi L. et al.: Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract]. J. Hypertens. 2000; 18(supl. 2): S65.
2. Głuszek J., Pawlaczyk K.: Działania niepożądane antagonistów wapnia. Choroby Serca i Naczyń 2006; 3: 18-31.
3. Charakterystyka produktu leczniczego Primacor [online: http://www.urpl.gov.pl/drugs/7758010].
4. Barrios V., Navarro A., Esteras A. et al.; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad): Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11: 95-100.
5. Barbagallo Sangiorgi G., Putignano E., Calcara L. et al.: Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S36-39.
6. James I.G.V., Jones A., Davies P.: A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J. Hum. Hypertens. 2002; 16: 605-610.
7. Morisco C., Trimarco B.: Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a doubleblind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S26-30.
8. Notarbartolo A., Rengo F., Scafidi V. et al.: Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr. Ther. Res. 1999; 60: 228-236.
9. Epstein M.: Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis. 2001; 3: 398-407.
10. Lund-Johansen P., Stranden E., Helberg S. et al.: Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 2003; 21: 1003-1010.
11. Ioulios P., Charalampos M., Efrossini T.: The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms. Dermatol. Online J. 2003; 9: 6.
12. Leonetti G.: The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 1999; 8: 92-101.
13. Fogari R., Malamani G.D., Zoppi A. et al.: Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel group study. Curr. Ther. Res. Clin. Exp. 2000; 61: 850-862.
14. Bang L.M., Chapman T.M., Goa K.L.: Lercanidipine. A Review of its Efficacy in the Management of Hypertension. Drugs 2003; 63: 2449-2472.
15. McClellan K.J., Jarvis B.: Lercanidipine: a review of its use in hypertension. Drugs 2000; 60: 1123-40.
16. Papavassiliou M.V., Vyssoulis G.P., Karpanou E.A. et al.: Side effects of antihypertensive treatment with calcium channel antagonists. Am. J. Hypertens. 2001; 14: 114A.
17. Barrios V., Escobar C., de la Figuera M. et al.: Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc. Ther. 2008; 26: 2-9.
18. Sabbatini M., Leonardi A., Testa R. et al.: Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-779.
19. Robles N.R., Romero B., de Vinuesa E.G. et al.: Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren. Fail. 2010; 32: 192-197.
20. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27: 73-80.
21. Leonardi A., Poggesi E., Taddei L. et al.: In vitro calcium antagonist activity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S10-18.
22. Meredith P.A.: Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Invest. Drug. 1999; 8: 1043-1062.
23. Guarneri L., Angelico P., Ibba M. et al.: Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittel Forschung 1996; 46: 15-24.
24. Angelico P., Guarneri L., Leonardi A. et al.: Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J. Pharm. Pharmacol. 1999; 51: 709-714.
25. Sironi G., Colombo D., Greto L. et al.: Antihypertensive activity of lercanidipine and its enantiomers in animal models. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S33-40.
26. Testa R., Rimoldi O., Sironi G. et al.: Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine and its enantiomers in conscious dogs. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): 78-85.
27. Guarneri L., Sironi G., Angelico P. et al.: In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S25-32.
28. Bianchi G., Passoni A., Griffini P.L.: Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol. Res. 1989; 21: 193-200.
29. Soma M.R., Natali M., Donetti E. et al.: Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br. J. Pharmacol. 1998; 125: 1471-1476.
30. Corsini A., Bonfatti M., Quarato P. et al.: Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol. 1996; 28: 687-694.
31. Harada N., Yamaguchi H., Shigematsu K. et al.: Effects of lercanidipine, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats [abstract]. SHR Congress. 1999 Aug 26-27; Sapporo.
32. Fogari R., Mugellini A., Corradi L. et al.: Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract]. J. Hypertens. 2000; 18(supl. 2): S65.